Skip to main content
. 2016 Feb 24;7(13):16619–16635. doi: 10.18632/oncotarget.7672

Figure 10. Systemic administration of liposomal FOXM1 siRNA inhibits tumor growth in an orthotopic mouse MDA-MB-231 xenograft model.

Figure 10

(A) MDA-MB-231 cells were injected into mammary fat pat of female athymic nude mice. Mice were either treated with liposomal nanoparticles incorporating control siRNA or FOXM siRNA (#1, #2) (0.3 mg/kg or about 8 μg/mouse, i.v once a week from tail vein, n = 5 mice/group). Tumors sizes were measured weekly. The tumor volumes growth curve of MDA-MB-231 are shown as mean ± SD of the group and ±SEM, p-values obtained with Student's t-test. (B) Tumor samples of MDA-MB-231 xenografts from control siRNA and FOXM1siRNA -treated mice were analyzed by Western blot analysis for FOXM1 expression.